D-0672-2017 Class III Terminated

Recalled by Valeant Pharmaceuticals North America LLC — Bridgewater, NJ

FDA drug recall D-0672-2017 was initiated by Valeant Pharmaceuticals North America LLC on Mar 20, 2017 and is designated Class III. Reason for recall: Discoloration. The recall status is terminated (terminated Jun 14, 2019). Affected quantity: 38,767 units.

Recall details

Product Type
Drugs
Report Date
Apr 26, 2017
Initiation Date
Mar 20, 2017
Termination Date
Jun 14, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
38,767 units

Product description

CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc Long Beach, CA 90806 Made in USA. Product SKU 301876102042, NDC 0187-6102-04

Reason for recall

Discoloration.

Distribution pattern

nationwide

Code information

Lot #: 15J1277, Exp. 04/2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0672-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0672-2017. Report a data issue: hello@regdatalab.com.